1.Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis.
Dae Myung JUE ; Kye Im JEON ; Jae Yeon JEONG
Journal of Korean Medical Science 1999;14(3):231-238
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint swelling and progressive destruction of cartilage and bone. Current RA treatments are largely empirical in origin and their precise mechanism of action is uncertain. Increasing evidence shows that chronic inflammatory diseases such as RA are caused by prolonged production of proinflammatory cytokines including tumor necrosis factor (TNF) and interleukin 1 (IL-1). The nuclear factor kappaB (NF-kappaB) plays an essential role in transcriptional activation of TNF and IL-1. NF-kappaB is induced by many stimuli including TNF and IL-1, forming a positive regulatory cycle that may amplify and maintain RA disease process. NF-kappaB and enzymes involved in its activation can be a target for anti-inflammatory treatment. Aspirin and sodium salicylate inhibit activation of NF-KB by blocking IkappaB kinase, a key enzyme in NF-kappaB activation. Glucocorticoids suppress expression of inflammatory genes by binding glucocorticoid receptor with NF-kappaB, and increasing expression of inhibitory protein of NF-kappaB, IkappaBalpha. Sulfasalazine and gold compounds also inhibit NF-kappaB activation. Continuing advances in our understanding of action mechanism of antirheumatic agents will benefit the future development of RA regimens with greater efficacy and less toxicity.
Animal
;
Antirheumatic Agents/therapeutic use*
;
Arthritis, Rheumatoid/therapy*
;
Arthritis, Rheumatoid/metabolism
;
Arthritis, Rheumatoid/immunology
;
Cytokines/immunology
;
Cytokines/genetics
;
Gene Expression Regulation
;
Human
;
Macrophages/immunology
;
NF-kappa B/metabolism*
;
NF-kappa B/immunology
;
NF-kappa B/biosynthesis
;
Tumor Necrosis Factor/genetics
2.Expression of CCR2A, an isoform of MCP-1 receptor, is increased by MCP-1, CD40 ligand and TGF-beta in fibroblast like synoviocytes of patients with RA.
Mi La CHO ; Bo Young YOON ; Ji Hyeon JU ; Young Ok JUNG ; Joo Yeon JHUN ; Mi Kyung PARK ; Sung Hwan PARK ; Chul Soo CHO ; Ho Youn KIM
Experimental & Molecular Medicine 2007;39(4):499-507
Cytokine and chemokine receptors play a key role in inflammation caused by rheumatoid arthritis (RA). Two isoforms of human CC chemokine receptor R2 (CCR2), the receptor of monocyte chemoattractant protein 1 (MCP-1), have been identified but their relative expression in fibroblast-like synoviocytes (FLS) and their contribution to inflammatory responses mediated by MCP-1 or inflammatory cytokines in patients with RA remain uncertain. We examined the pattern of expression of two CCR2 isoforms upon stimulation by proinflammatory cytokines and CD40 ligation. FLS were prepared from the synovial tissues of RA patients and cultured in the presence of MCP-1, soluble CD40 ligand (sCD40L), TGF-beta, IL-1beta, IL-18, IL-15, and LPS. CCR2A and CCR2B expression was examined by immunohistochemistry, RT-PCR and western blot analysis. IL-15, TNF-alpha and MCP-1 production was determined by ELISA. Immunohistochemistry showed that CCR2A is highly expressed in RA synovium compared with OA synovium. Transcripts of both CCR2A and CCR2B were detected in FLS. Exogenous MCP-1, CD40L, TGF-beta, and IL-15 significantly increased the expression of CCR2A but not CCR2B. Exposure of FLS to sCD40L caused strong upregulation of CCR2A but not of CCR2B protein expression. MCP-1 increased the proliferation of FLS and the production of IL-15, TNF-alpha, and IL-18. Because CCR2A is the main target of regulation by cytokines and CD40 ligation, the relatively higher expression of CCR2A on the cell surface suggests that this isoform of MCP-1 receptor functions as the principal mediator of inflammatory signals in RA FLS.
Arthritis, Rheumatoid/*metabolism
;
CD40 Ligand/*pharmacology
;
Cells, Cultured
;
Chemokine CCL2/*pharmacology
;
Chemokines/biosynthesis
;
Fibroblasts/*metabolism
;
Humans
;
Protein Isoforms
;
Receptors, CCR2/*biosynthesis
;
Synovial Membrane/*pathology
;
Transforming Growth Factor beta/*pharmacology
3.Sjogren's Syndrome Presenting as Remitting Seronegative Symmetric Synovitis with Pitting Edema(RS3PE).
Young Mi CHOI ; Dong Hyuk SHEEN ; Yun Jong LEE ; Eun Bong LEE ; Yeong Wook SONG
Journal of Korean Medical Science 2003;18(4):606-608
Remitting seronegative symmetric synovitis with pitting edema (RS3 PE) syndrome is characterized by symmetrical and acute synovitis, pitting edema, the absence of rheumatoid factor, increased acute phase reactants, lack of bony erosions on radiography, and benign and short clinical course. Half of all patients with Sjogren's syndrome experience arthritis during the disease course. We here describe the first case of Sjogren's syndrome presenting as RS3PE. She had swelling in knees, ankles, and wrists. After then the swelling spread to her lower legs, feet, face, and both hands. She was admitted to another hospital and was suspected of lupus or rheumatoid arthritis. Three months later, she had dry mouth and had lower lip biopsy. She was admitted to this hospital due to development of swelling in face and lower legs for 3 days. On physical examination, she had pitting edema in both hands and feet dorsum. Laboratory test showed elevated erythrocyte sedimentation rate, positivity of rheumatoid factor, anti-nuclear antibody, and anti-Ro antibody. There was no erosion in the hands radiography. Schirmer's test and lip biopsy was compatible with Sjogren's syndrome. She was diagnosed RS3 PE and Sjogren's syndrome. She was begun with prednisolone and her symptoms improved gradually.
Adult
;
Antibodies, Antinuclear/biosynthesis
;
Arthritis/complications
;
Biopsy
;
Blood Sedimentation
;
Diagnosis, Differential
;
Edema/*diagnosis
;
Female
;
Human
;
Lymphocytes/pathology
;
Prednisolone/therapeutic use
;
Rheumatoid Factor/biosynthesis
;
Salivary Glands/pathology
;
Sjogren's Syndrome/*diagnosis
;
Syndrome
;
Synovitis/*diagnosis
4.Expression of sTNFR-IgGFc fusion gene in endothelial cell and its application in gene therapy for rheumatoid arthritis.
Jie HE ; Li-Hong YAO ; Ai-Jun CHEN ; Hong YU ; Run-Qing JIA ; Cong-Sheng CHENG ; Li-Fang HUAN ; Zhi-Qing ZHANG
Chinese Journal of Biotechnology 2006;22(3):378-383
Tumor necrosis factor alpha (TNFalpha) is a pro-inflammatory cytokine, acting as a regulator of inflammation and immunity. TNFalpha plays a critical role in the pathogenesis of rheumatoid arthritis. Blocking of TNFa activity suppressed inflammatory tissue damage. In present study, the chimeric gene of soluble TNF receptor and IgG Fc fragment (sTNFR-IgG FC) was cloned into the mammalian cell expression vector pStar. When the plamid pStar/sTNFR-IgGFc-GFP was transfected into endothelial cells, a considerable expression of the sTNFR-IgG Fc fusion protein was detected. Moreover, the product in 100microL expression supernatant could completely antagonize the cytolytic effect of 1ng TNFa on L929 cells, even at 1/64 dilution. Then the plasmid was delivered into CIA-induced rheumatoid arthritis mice by tail vein injection. The expression of sTNFR-IgG Fc was detected in liver by RT-PCR. Animals in treatment group showed reduced symptoms of arthritis and more active. This treatment induced decrease of synovial incrassation and prevented the cartilage destruction of the mice RA model. These results show that tail vein injection is an effective way for gene therapy and sTNFR-IgGFc expression plasmid is potential for the treatment of rheumatoid arthritis.
Animals
;
Arthritis, Rheumatoid
;
chemically induced
;
therapy
;
Collagen Type II
;
Endothelial Cells
;
metabolism
;
Escherichia coli
;
genetics
;
metabolism
;
Etanercept
;
Genetic Therapy
;
Humans
;
Immunoglobulin G
;
biosynthesis
;
genetics
;
therapeutic use
;
Male
;
Mice
;
Mice, Inbred DBA
;
Receptors, Tumor Necrosis Factor
;
biosynthesis
;
genetics
;
therapeutic use
;
Recombinant Fusion Proteins
;
biosynthesis
;
genetics
;
therapeutic use
;
Transfection
;
Tumor Necrosis Factor-alpha
;
metabolism
5.Therapeutic effect of dimethyl dimethoxy biphenyl dicarboxylate on collagen-induced arthritis in rats.
Roba M TALAAT ; Amira S ABO-EL-ATTA ; Sabah M FAROU ; Karima I EL-DOSOKY
Chinese journal of integrative medicine 2015;21(11):846-854
OBJECTIVETo study the effect of oral administration of dimethyl dimethoxy biphenyl dicarboxylate (DDB) on adjusting angiogeneic/inflammatory mediators and ameliorating the pathology of bones in rats with collagen-induced arthritis (CIA).
METHODSWistar rat model of CIA was set up using bovine collagen type II. Fifty rats were divided into five groups randomly: normal, CIA model, DDB treatment, methotrexate (MTX) treatment, and combined DDB+MTX treatment. Ankle joints of rats were imaged with digital X-ray machine to show the destruction of joints. Fore and hind paw and knee joints were removed above the ankle joint then processed for haematoxylin and eosin staining. Plasma levels of vascular endothelial growth factor (VEGF), platelet derived growth factor, interleukin-8 (IL-8), IL-4, tumor necrosis factor α (TNF-α), and cyclooxygenase-2 (COX-2) were quantified by enzyme-linked immunosorbent assay. Nitric oxide levels were detected by Griess reagent.
RESULTSCompared with the CIA model group, a remarkable reduction in various angiogenic (VEGF and IL-8) and inflammatory mediators (TNF-α, IL-4 and COX-2) after treatment with DDB either alone or combined with MTX P<0.05 or P<0.01). Histopathological and X-ray findings were confirmatory to the observed DDB anti-arthritic effect. The DDB-treated group showed amelioration in signs of arthritis which appeared essentially similar to normal.
CONCLUSIONOur data shed light on the therapeutic efficacy of DDB in experimental rheumatoid arthritis (RA) compared with a choice drug (MTX) and it may be offered as a second-line drug in the treatment of RA.
Animals ; Arthritis, Experimental ; chemically induced ; diagnostic imaging ; drug therapy ; pathology ; Arthritis, Rheumatoid ; diagnostic imaging ; drug therapy ; pathology ; Collagen ; Cyclooxygenase 2 ; blood ; Dioxoles ; therapeutic use ; Enzyme-Linked Immunosorbent Assay ; Female ; Interleukin-4 ; blood ; Interleukin-8 ; blood ; Methotrexate ; therapeutic use ; Nitric Oxide ; biosynthesis ; Platelet-Derived Growth Factor ; analysis ; Radiography ; Rats ; Rats, Wistar ; Tumor Necrosis Factor-alpha ; blood ; Vascular Endothelial Growth Factor A ; blood
6.Engagement of Toll-Like Receptor 3 Induces Vascular Endothelial Growth Factor and Interleukin-8 in Human Rheumatoid Synovial Fibroblasts.
Su Jin MOON ; Mi Kyung PARK ; Hye Jwa OH ; Seon Yeong LEE ; Seung Ki KWOK ; Mi La CHO ; Ji Hyeon JU ; Kyung Su PARK ; Ho Youn KIM ; Sung Hwan PARK
The Korean Journal of Internal Medicine 2010;25(4):429-435
BACKGROUND/AIMS: Angiogenesis, which is a critical step in the initiation and progression of rheumatoid arthritis (RA), involves pro-angiogenic factors, including interleukin (IL)-8 and vascular endothelial growth factor (VEGF). We investigated the role of Toll-like receptor 3 (TLR3) in the regulation of pro-angiogenic factors in RA fibroblast-like synoviocytes (FLS). METHODS: FLS were isolated from RA synovial tissues and stimulated with the TLR3 ligand, poly (I:C). The levels of VEGF and IL-8 in the culture supernatants were measured using enzyme-linked immunosorbent assays, and the mRNA levels were assessed by semiquantitative reverse transcription-polymerase chain reaction. The expression patterns of VEGF and IL-8 in the RA synovium and osteoarthritis (OA) synovium were compared using immunohistochemistry. RESULTS: The expression levels of TLR3, VEGF, and IL-8 were significantly higher in the RA synovium than in the OA synovium. VEGF and IL-8 production were increased in the culture supernatants of RA FLS stimulated with poly (I:C), and the genes for these proteins were up-regulated at the transcriptional level after poly (I:C) treatment. Treatment with inhibitors of nuclear factor-kappaB (NF-kappaB), i.e., pyrrolidine dithiocarbamate and parthenolide, abrogated the stimulatory effect of poly (I:C) on the production of VEGF and IL-8 in RA FLS. CONCLUSIONS: Our results suggest that the activation of TLR3 in RA FLS promotes the production of proangiogenic factors, in a process that is mediated by the NF-kappaB signaling pathway. Therefore, targeting the TLR3 pathway may be a promising approach to preventing pathologic angiogenesis in RA.
Arthritis, Rheumatoid/drug therapy/*etiology/metabolism
;
Cells, Cultured
;
Fibroblasts/metabolism
;
Humans
;
Interleukin-8/analysis/*biosynthesis/genetics
;
NF-kappa B/physiology
;
Neovascularization, Pathologic/etiology
;
RNA, Messenger/analysis
;
Synovial Membrane/cytology/*metabolism
;
Toll-Like Receptor 3/analysis/*physiology
;
Vascular Endothelial Growth Factor A/analysis/*biosynthesis/genetics
7.Synthesis and antiinflammation activity of aromatic aminoketone compounds, a new type of PAF-receptor antagonist.
Li-yuan MOU ; Zi-yun LIN ; Jie LIU ; Qi-dong ZHANG ; Li-ya ZHU ; Wen-jie WANG ; Zhen-gui NIE ; Yu HE
Acta Pharmaceutica Sinica 2008;43(9):917-925
A series of aromatic aminoketones were synthesized by Mannich reaction. Structures of these compounds were confirmed by 1H NMR, MS and HRMS or element analysis. Pharmacological screening showed that most target compounds inhibited the release of beta-glucuronidase in polymorphonuclear leucocytes by PAF (platelet activating factor) and compounds MA12, MA13, MA18, MA21 and MA33 were more active. The study suggests that target compounds are potential PAF receptor antagonists and their anti-inflammatory activities are due to the inhibition of release of lysosomal enzyme.
Animals
;
Anti-Inflammatory Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Arthritis, Rheumatoid
;
drug therapy
;
Glucuronidase
;
metabolism
;
Ketones
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Macrophages, Peritoneal
;
metabolism
;
Mice
;
Neutrophils
;
enzymology
;
Platelet Membrane Glycoproteins
;
antagonists & inhibitors
;
Rats
;
Receptors, G-Protein-Coupled
;
antagonists & inhibitors
;
Structure-Activity Relationship
;
Tumor Necrosis Factor-alpha
;
biosynthesis
8.Eupatilin Ameliorates Collagen Induced Arthritis.
Juryun KIM ; Youngkyun KIM ; Hyoju YI ; Hyerin JUNG ; Yeri Alice RIM ; Narae PARK ; Seung Min JUNG ; Sung Hwan PARK ; Ji Hyeon JU
Journal of Korean Medical Science 2015;30(3):233-239
Eupatilin is the main active component of DA-9601, an extract from Artemisia. Recently, eupatilin was reported to have anti-inflammatory properties. We investigated the anti-arthritic effect of eupatilin in a murine arthritis model and human rheumatoid synoviocytes. DA-9601 was injected into collagen-induced arthritis (CIA) mice. Arthritis score was regularly evaluated. Mouse monocytes were differentiated into osteoclasts when eupatilin was added simultaneously. Osteoclasts were stained with tartrate-resistant acid phosphatase and then manually counted. Rheumatoid synoviocytes were stimulated with TNF-alpha and then treated with eupatilin, and the levels of IL-6 and IL-1beta mRNA expression in synoviocytes were measured by RT-PCR. Intraperitoneal injection of DA-9601 reduced arthritis scores in CIA mice. TNF-alpha treatment of synoviocytes increased the expression of IL-6 and IL-1beta mRNAs, which was inhibited by eupatilin. Eupatilin decreased the number of osteoclasts in a concentration dependent manner. These findings, showing that eupatilin and DA-9601 inhibited the expression of inflammatory cytokines and the differentiation of osteoclasts, suggest that eupatilin and DA-9601 is a candidate anti-inflammatory agent.
Animals
;
Anti-Inflammatory Agents/pharmacology/*therapeutic use
;
Arthritis, Experimental/chemically induced/*drug therapy
;
Arthritis, Rheumatoid/drug therapy/pathology
;
Cell Differentiation/*drug effects
;
Cells, Cultured
;
Collagen Type II
;
Cytokines/biosynthesis
;
Disease Models, Animal
;
Drugs, Chinese Herbal/therapeutic use
;
Female
;
Flavonoids/pharmacology/*therapeutic use
;
Humans
;
Inflammation/drug therapy/immunology
;
Interleukin-1beta/genetics/metabolism
;
Interleukin-6/genetics/metabolism
;
Lymph Nodes/cytology
;
Mice
;
Mice, Inbred DBA
;
Monocytes/cytology
;
Osteoclasts/*cytology
;
Plant Extracts/pharmacology
;
RNA, Messenger/biosynthesis
;
Synovial Membrane/cytology
;
T-Lymphocytes, Regulatory/cytology/immunology
;
Tumor Necrosis Factor-alpha/pharmacology